Biogen is cutting ties with Aduhelm, the Alzheimer’s disease drug that won a landmark but controversial regulatory approval and then became a commercial flop. Development and commercialization of ...

For Biogen’s ill-fated Alzheimer’s disease drug Aduhelm, a narrow Medicare reimbursement policy is taking a toll beyond sales and on the company’s clinical development plan. Biogen has pulled the plug ...

More than two years after Aduhelm's controversial and ill-fated FDA accelerated approval, Biogen is discontinuing the Alzheimer's disease therapy after walking a rocky path. Wednesday, Biogen said ...

Biogen's new management is diversifying its product portfolio and optimizing costs, but faces significant risks from market share loss and generic competition. The fair valuation of Biogen shares is ...

For decades, Biogen has built a legacy in neuroscience — having brought to market drugs that have changed lives for multiple sclerosis, Alzheimer’s disease, spinal muscular atrophy, and more. But ...

Biogen isn’t shy about aspirations to expand beyond neurology and further establish itself in immunology and rare diseases. Recent business development deals have focused on enhancing the company’s ...

Biogen is an intriguing stock that occupies one of the leading positions in the central nervous system therapeutic market. On May 1, it released fairly strong financial results for the first quarter ...

The Cambridge biotech company Biogen has roots in the 1970s — the dawn of biotechnology. Its big successes include developing a series of powerful and lucrative medicines that transformed the ...

During the last three months, 12 analysts shared their evaluations of Biogen (NASDAQ:BIIB), revealing diverse outlooks from bullish to bearish. The table below provides a snapshot of their recent ...